Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 12;7(10):ofaa346.
doi: 10.1093/ofid/ofaa346. eCollection 2020 Oct.

ART Adherence, Resistance, and Long-term HIV Viral Suppression in Postpartum Women

Andrew D Redd  1   2 , Elton Mukonda  3 , Nai-Chung Hu  3 , Tamsin K Philips  3 , Allison Zerbe  4 , Maia Lesosky  3 , Nei-Yuan Hsiao  5   6 , William Clarke  7 , Steven J Reynolds  1   2   8 , Elaine J Abrams  4   9 , Landon Myer  3   10
Affiliations

ART Adherence, Resistance, and Long-term HIV Viral Suppression in Postpartum Women

Andrew D Redd et al. Open Forum Infect Dis. .

Abstract

HIV+ South African women who achieved viral suppression during routine antenatal care, but later experienced a viremic episode (viral load >1000 copies/mL), were examined for presence of antiretrovirals and classified as "nonadherers" or "suboptimal adherers." Women were tested for drug resistance mutations (DRMs) at several time points and underwent viral load testing 36-60 months postpartum. Suboptimal adherers were more likely to have DRM detected during their viremic episode (P = .03) and at a subsequent viremic time point (P = .05). There was no difference in levels of viral suppression 36-60 months later in women with DRM detected vs women who had no evidence of DRM (P = .5).

Keywords: ART adherence; atiretrovirals; drug resistance; postpartum women.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Representative schematic of testing strategy for women who achieved viral suppression and subsequently experienced a viremic episode. Original viral load measurements (filled circles), next-generation sequencing–based drug resistance mutation detection (blue arrow), direct mass spectrometry–based antiretroviral testing (green arrow) are shown, as well as longitudinal viral load testing (open arrow). Abbreviations: ART, antiretroviral therapy; DRM, drug resistance mutation.
See this image and copyright information in PMC

References

    1. Kumwenda NI, Hoover DR, Mofenson LM, et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med 2008; 359:119–29. - PubMed
    1. Taha S, Taylor G. The strength of the WHO recommendations for the prevention of mother-to-child transmission of HIV. HIV Med 2015; 16:28–9.
    1. Knettel BA, Cichowitz C, Ngocho JS, et al. Retention in HIV care during pregnancy and the postpartum period in the option B+ era: systematic review and meta-analysis of studies in Africa. J Acquir Immune Defic Syndr 2018; 77:427–38. - PMC - PubMed
    1. Myer L, Redd AD, Mukonda E, et al. Antiretroviral adherence, elevated viral load, and drug resistance mutations in human immunodeficiency virus–infected women initiating treatment in pregnancy: a nested case-control study. Clin Infect Dis 2020; 70:501–8. - PMC - PubMed
    1. Nachega JB, Uthman OA, Anderson J, et al. Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: a systematic review and meta-analysis. AIDS 2012; 26:2039–52. - PMC - PubMed